Beijing Tiantan Biological Products Co., Ltd. specializes in the discovery, production, and distribution of essential biopharmaceutical products across China. The company's portfolio encompasses a wide array of plasma-derived treatments, including human albumin, various immunoglobulins like intravenous, hepatitis B, tetanus, and rabies types, alongside critical coagulation factors such as Factor VIII and prothrombin complex. Additionally, it develops recombinant products and a selection of preventive vaccines. Established in 1998 and based in Beijing, China, the company is recognized as a leader within the Chinese blood product sector, commanding the largest plasma collection volume in the domestic market, reaching 2,415 tons in 2023 and accounting for 20% of the market share. Beijing Tiantan Biological is a subsidiary operating under China National Biotec Group Company Limited, itself a part of Sinopharm, and holds a significant role in national blood product reserves. Recent innovations include the approval of its fourth-generation 10% Intravenous Immunoglobulin, which utilizes a chromatography process, and the marketing authorization for its recombinant human coagulation factor VIII for injection.